Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. covers events occurring between March 28, 2019, and April 22, 2019, with the report dated April 18, 2019. The filing details unregistered sales of equity securities and debt restructuring activities.
Key Financial Metrics and Transactions
- Debt Repayment: Repaid $944,400 in outstanding convertible notes (including accrued interest and prepayment premiums) between March 29 and April 16, 2019.
- New Debt Issuance: Issued convertible promissory notes with a principal amount of $760,000 for cash proceeds of $728,280 between April 8 and April 12, 2019. These notes bear 12% annual interest and mature between October 2019 and January 2020.
- Debt-for-Equity Swap: Issued 1,137,274 shares of common stock to settle $437,228 of outstanding indebtedness (including interest and fees) between March 28 and April 22, 2019.
- Equity Issuance: Issued 80,000 shares of common stock at $0.70 per share to a Scientific Advisory Board member on April 9, 2019, accompanied by a five-year warrant for 80,000 shares at $1.00 per share.
- Additional Equity: Issued 68,873 shares of common stock to a lender in connection with a convertible note issuance.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the period.
Material Changes and Unusual Items
The primary material change is the significant restructuring of the company's capital structure through a combination of debt repayment, new debt financing, and debt conversion into equity. The issuance of convertible notes includes a conversion price generally equal to 58% of the fair value of the common stock, which represents a significant discount and potential dilution.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities. The transactions relied upon exemptions under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, indicating the company is actively managing liquidity through private placements rather than public offerings.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact from the 1,137,274 shares issued for debt and the 148,873 shares issued for cash/warrants.
- Confirm the fair value of the common stock used to calculate the 58% conversion price for the new convertible notes.
- Review the company's cash position to ensure it can service the new $760,000 debt obligation and the 12% interest rate.
- Check subsequent filings for any default on the new notes or further debt-for-equity conversions.